1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Lupin Limited

Lupin Limited

LUPIN.BO
Lupin LimitedIN flagBombay Stock Exchange
2,489.85
INR
-2.60
- -
1.14TMarket Cap
Lupin Limited
LUPIN.BO
(Bombay Stock Exchange)

Recent

price

2,489.85

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
130.59
155.7
211.35
247.52
280.39
302.9
376.68
344.19
316.6
334.49
329.31
356.64
357.82
431.78
486.57
601.78
500.66
Revenue per Share
19.36
19.43
29.39
40.99
53.54
50.23
56.69
5.56
13.41
-5.95
26.84
-33.65
9.46
42.05
71.95
116.75
81.09
Basic EPS, GAAP
8.29
12.54
27.98
44.73
60.89
-8.5
91.18
38.76
36.84
32.45
40.19
8.09
8.74
59.74
28.89
115.59
- -
Free Cash Flow per Basic Share
2.75
3.17
3.21
7.18
3
7.48
7.49
7.49
4.97
5
6.01
6.5
4.01
4.02
8.01
12
- -
Dividend per Share
60.27
75.6
2
2
151.24
192.13
239.34
235.49
242.67
227.96
247.07
206.57
211.72
247.66
310.5
2
- -
Book Value per Share
63.2
74.83
103.23
139
165.37
91.23
126.74
144.31
154.62
194.98
223.82
200.23
186.71
224.43
275.42
364.46
- -
Tangible Book Value per Share
446
446
447
448
449
450
451
452
452
453
453
454
455
455
456
457
456
Basic Weighted Avg Shares
58,190
69,512
94,500
110,887
125,860
136,339
169,928
155,522
143,180
151,428
149,270
161,928
162,700
196,563
221,921
274,875
228,415
Sales/Revenue/Turnover
17.58
17.88
20.88
25.49
26.45
23.39
22.84
13.31
11.61
9.17
11.65
3.4
5.47
14.23
18.51
53.41
27.46
Operating Margin (%)
1,712
2,275
3,322
2,610
4,347
4,871
9,122
10,859
10,850
11,596
8,874
16,587
8,807
9,956
11,693
13,755
11,070
Depreciation Expense
8,626
8,676
13,142
18,364
24,032
22,607
25,575
2,513
6,066
-2,694
12,165
-15,280
4,301
19,145
32,816
53,328
36,993
Net Income, GAAP
11.56
25.8
30.35
33.98
28.42
31.82
27.62
52.75
63.02
152.81
26.75
- -
37.52
20.09
17.65
22.07
16.12
Effective Tax Rate (%)
14.82
12.48
13.91
16.56
19.09
16.58
15.05
1.62
4.24
-1.78
8.15
-9.44
2.64
9.74
14.79
19.4
16.2
Profit Margin (%)
9,968
12,220
21,362
34,709
43,407
48,262
58,323
71,140
77,237
61,880
55,503
41,812
31,859
49,462
78,372
113,761
- -
Working Capital
2,992
4,330
2,471
1,510
1,018
53,739
56,478
64,245
66,417
20,159
2,748
3,638
2,139
1,553
20,305
21,383
- -
LT Debt
33,326
40,852
52,636
69,985
91,973
111,954
135,321
136,171
137,891
125,812
138,581
122,220
125,428
143,734
172,944
225,134
- -
Total Equity
22.18
18.19
22.66
26.6
27.5
15.48
14.07
4.61
2.85
-3.51
6.62
- -
3.25
12.74
16.61
43.25
- -
Return on Invested Capital (%)
34.57
19.49
40.77
170.42
58.46
19.75
15.27
1.74
3.72
-2.46
7.74
- -
4.04
14.84
20.6
42.68
91.03
Return on Capital (%)
62.18
28.63
75.85
2,048.49
69.88
29.29
26.3
2.34
5.61
-2.53
11.31
-14.85
4.53
18.32
25.8
74.83
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
ST Debt
- -
34,173
- -
LT Borrowings
- -
17,662
- -
LT Finance Leases
- -
2,643
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
457
- -
Market Capitalization
1,071,912
924,159
884,075

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
Total Current Assets
- -
167,986
- -
Cash, Cash Equivalents & STI
- -
30,201
- -
Accounts Receivable, Net
- -
54,971
- -
Inventories
- -
54,764
- -
Total Current Liabilities
- -
89,614
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
34,173
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.01%
11.18%
30.18%
Free Cash Flow
-46.43%
152.3%
300.73%
Net Income, GAAP
-50.64%
25.06%
62.51%
Sales/Revenue/Turnover
7.91%
13.31%
23.86%
Total Cash Common Dividend
10.82%
24.06%
50.1%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
47,421
49,392
50,799
48,951
196,563
2025
55,143
54,970
56,186
55,622
221,921
2026
61,638
71,004
73,919
- -
274,875

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9.94
10.78
13.47
- -
42.05
2025
17.58
18.7
18.75
16.93
71.95
2026
26.7
25.74
31.96
- -
116.75

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
4.02
2025
- -
- -
- -
- -
8.01
2026
- -
- -
- -
- -
12
Similar Companies
PT Phapros, Tbk (PEHA.JK)
DMK Pharmaceuticals Corporation (0A4X.L)
Sigachi Industries Limited (SIGACHI.NS)
HUTCHMED (China) Limited (HCM)
Verano Holdings Corp. (VRNO.CN)
Jiangsu Hengrui Pharmaceuticals Co.,Ltd (1276.HK)
Business
Lupin Limited is an Indian multinational pharmaceutical company that develops, manufactures and markets a broad portfolio of branded and generic formulations, active pharmaceutical ingredients (APIs), biosimilars, specialty drugs and over-the-counter (OTC) products across key therapeutic areas including anti-tuberculosis, cardiovascular, diabetes, respiratory, anti-infectives, central nervous system, paediatrics, oncology, ophthalmology and women's health; its offerings encompass generics where it ranks among the world's top ten companies with leadership in the US market for over 70 products in the top three by share, biosimilars such as etanercept for rheumatoid arthritis and psoriasis available in Japan, India and Europe, specialty branded medications focused on women's health in the US and rare diseases in Europe, OTC products like bowel regulators, intimate hygiene solutions, health supplements and sanitizers through divisions such as LupinLife in India and Pharmacy Action in Australia, APIs supplied to over 70 countries, tech-driven solutions including diagnostics services via Lupin Diagnostics, digital therapeutics like LYFE for cardiac care and ATHARV ABILITY for neurological rehabilitation, and global institutional business products for underserved communities combating diseases like tuberculosis; the company also provides patient support programs such as Humrahi for diabetes and heart health, Anya chatbot for health queries, Fight TB app and Joint Airways Initiative for asthma education. Founded in 1968 by Dr. Desh Bandhu Gupta and headquartered in Mumbai, India, Lupin operates 15 state-of-the-art manufacturing facilities across India, the US, Brazil and Mexico, with products distributed in over 100 countries and significant revenue contributions from the US (38%), India (34%) and other developed markets. In recent developments, Lupin's subsidiary Nanomi signed a definitive agreement in 2025 to acquire VISUfarma for €190 million to bolster its European ophthalmology portfolio in dry eye, glaucoma and retinal health, expected to close by year-end; the company announced plans for a new USD 250 million manufacturing facility in Coral Springs, Florida, spanning 70,000 square feet for critical respiratory therapies; it entered an exclusive licensing agreement with Valorum for biosimilar Armlupeg (pegfilgrastim-unne) in the US; and in 2024 acquired nine brands from Medical Nutritional Institute in South Africa including AntaGolin and NeuroVance.